At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jul 17, 2026 at 07:15 ET
Evaxion will present three-year Phase 2 data for personalized cancer vaccine EVX-01 at ESMO 2026 (Oct 23-27). The third-year data includes a stand-alone therapy cohort, offering insight into EVX-01's effect without anti-PD-1 combination. Prior two-year data showed a 75% ORR and durable responses, but the stock has historically declined on prior neutral reports, suggesting limited market enthusiasm for early-stage data milestones.
- Three-year Phase 2 data for EVX-01 will be presented at ESMO Congress 2026 (Oct 23-27, Madrid).
- Third-year data includes a subset of patients receiving EVX-01 as stand-alone therapy (no anti-PD-1 combination).
- Prior two-year data showed 75% ORR (12/16 patients), 92% durable response at 2 years, and no relapses.
- EVX-01 induced immune response in all patients; 86% of targeted neoantigens generated T-cell responses.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access